NCT06323018 Effects of Remote Ischaemic Preconditioning in Cemented Hip Arthroplasty.
| NCT ID | NCT06323018 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Tartu |
| Condition | Osteoarthritis, Hip |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-03-20 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-03-20 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Total joint arthroplasty is one of the best treatment options for end-stage osteoarthritis. Cemented hip arthroplasty is mainly indicated for elderly patients with poor bone quality and multiple comorbidities. Bone cement implantation syndrome is associated with cemented hip arthroplasty and it has been shown to increase cardiovascular and renal complication and brain damage postoperatively. The aim of this project is to elucidate whether remote-ischemic preconditioning (RIPC) has multi-organ protective effect in cemented hip arthroplasty patients.
Eligibility Criteria
Inclusion Criteria: * age \>65 years * undergoing total hip cemented hip arthroplasty Exclusion Criteria: * previously diagnosed peripheral artery disease on both upper limb * RIPC is contraindicated
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06323018 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 90 Years, studying Osteoarthritis, Hip. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06323018 currently recruiting?
Yes, NCT06323018 is actively recruiting participants. Contact the research team at kaspar.tootsi@kliinikum.ee for enrollment information.
Where is the NCT06323018 trial being conducted?
This trial is being conducted at Tartu, Estonia.
Who is sponsoring the NCT06323018 clinical trial?
NCT06323018 is sponsored by University of Tartu. The trial plans to enroll 200 participants.